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Blood transfusion, the main therapy for patients with severe 
thalassemia, is challenged by alloantibodies that can lead 
to hemolytic transfusion reactions. The use of prophylactic 
antigen-matched units is recommended, but serologic typing, 
before the first transfusion, is rarely performed and is not 
reliable after chronic transfusion. Patient DNA-based typing 
is a promising strategy, but clinical outcome data are lacking. 
The aim of this study was to determine the benefits of antigen-
matched transfusion guided by DNA-based typing in terms 
of new alloantibody formation and increases in mean pre-
transfusion hemoglobin (Hb) levels. We performed DNA-based 
typing on samples from 24 transfusion-dependent patients with 
thalassemia who had no serologic phenotyping performed before 
the first transfusion. These patients were then transfused with 
antigen-matched donor RBC units that were typed serologically. 
New alloantibody formation and mean pre-transfusion Hb 
levels were evaluated after implementing this extended common 
antigen-matching transfusion protocol. Sixty-three percent of the 
patients in this study were diagnosed as having beta-thalassemia 
Hb E. Alloantibodies were already present in 87.5 percent (21/24) 
of these patients, and most of these antibodies were multiple and/
or unidentified. After the enrollment, there were 717 transfusion 
episodes comprising 1209 RBC units. The number of RBC units 
transfused to each patient ranged from 22 to 119 units. At the 
median duration of 25.5 months (range 10–34 months), no new 
alloantibodies were detected since the beginning of the protocol. 
Seventy-four transfusion episodes in six patients were cross-
match-positive due to autoantibodies (patients 2, 4, 8, 9, and 14) or 
anti-Chido (patient 18) that had been identified before the study. 
There were no hemolytic transfusion reactions in this study. Five 
patients (patients 1, 2, 12, 15, and 20) showed increased mean 
pre-transfusion Hb levels (≥1 g/dL) and one patient (patient 16) 
had longer intervals between transfusions (compared with those 
before the protocol), suggesting longer RBC survival, although 
there was no statistical difference in the whole group. Our study 
highlights the benefits of DNA-based typing in chronically 
transfused patients with thalassemia who had no phenotyping 
data before the first transfusion. Patient DNA-based typing for 
antigen-matched transfusion is safe in thalassemia and allows 
us to obtain better-matched blood units for complicated patients. 
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Chronic transfusion in patients with thalassemia is 
often complicated by red blood cell (RBC) alloantibodies to 
the lacking antigens on the patients’ RBCs. The prevalence 
of alloantibodies ranges from 4.25 to 37 percent in patients 
with thalassemia.1–6 Clinically significant alloantibodies can 
shorten transfused erythrocyte survival due to hemolytic 
transfusion reactions. To reduce the alloantibody risk, 
RBC antigen serotyping for Rh (C, c, E, e) and MNS hybrid 
glycophorins, especially for MNS7 (Mia), is recommended 
before the first transfusion by our national thalassemia 
guidelines. Subsequently, Rh- and Mia-matched blood units 
are transfused.7 However, phenotyping data before the first 
transfusion are unavailable at our institute, and most patients 
with thalassemia have been receiving blood regularly since 
childhood.
Serologic methods are the standard for determining 
ABO, D, and common blood group antigens. Nevertheless, 
this approach in chronically transfused patients with 
thalassemia is inaccurate because of the contaminating 
donor erythrocytes in patient circulation. DNA-based typing 
is superior in situations of recent transfusions.8 Moreover, 
it can guide the antigen-matched transfusion in individual 
patients. Furthermore, autoantibodies are frequently found 
in patients with thalassemia, causing crossmatch problems.9 
The prevalence of autoantibodies is 0.47–28.2 percent by 
direct antiglobulin test and 57.6 percent by flow cytometry 
depending on study population and transfusion policy.10–13
In this study, we implemented DNA-based typing for 
chronically transfused patients with thalassemia and provided 
antigen-matched RBC units accordingly. A better-matched 
unit should prolong the RBC survival in vivo and thus increase 
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the next pre-transfusion hemoglobin (Hb). Pre-transfusion 
Hb is an important goal to reach to ensure blood transfusion 
effectiveness. The aim of this study was to determine the 
clinical benefits of this strategy in terms of new alloantibody 
formation and increases in the mean pre-transfusion Hb 
that suggest the longer survival of transfused RBCs. We also 
assessed patients’ clinical responses to crossmatch-positive, 
but antigen-matched, RBC transfusions and explored the 
predictors of Hb response in antigen-matched transfusions.
Materials and Methods
Patients and Interventions
In our tertiary care hospital with many referred patients 
with thalassemia, RBC phenotype data before the first 
transfusion are unavailable for most patients. Therefore, we 
enrolled this group of patients who previously had crossmatch 
problems or history of unsatisfactory pre-transfusion Hb 
after chronic transfusion. Patients who did not receive 
regular transfusion (n = 2) were excluded from our analysis. 
Patient history, transfusion records, pre-transfusion Hb, 
and alloimmunization history were retrieved from hospital 
records. DNA-based typing was performed from 2014 to 
2018. Determination of ABO, D, antibody screening, and 
crossmatching were performed before each transfusion using 
column agglutination technology (Ortho Clinical Diagnostics, 
Raritan, NJ). The study was approved by the institutional 
review board of the Faculty of Medicine, Chulalongkorn 
University, Thailand (Ethics Committee: 725/62).
Donor Phenotyping
Donor units were antigen matched using hemaggluti-
nation in gel cards (Bio-Rad; Cressier, Switzerland) for ABO, 
Rh (D, C, c, E, e), Mia, M, S, Jka, Jkb, Fya, Fyb, and Dia, since 
they are the most common clinically significant alloantibodies 
in Thailand.10,14 Genotyping was not performed on the donor 
blood components. Typing for Rh (C, c, E, e), Jka, Jkb, Fya, 
and Fyb was performed according to the manufacturer’s 
instructions (Bio-Rad). Anti-Mia and anti-M were produced 
by the Thai National Blood Centre, Thailand. S was assessed 
using the reagent antibody from CE-IMMUNDIAGNOSTIKA 
GmbH (Germany). Anti-Dia was produced in-house from 
patient sera with anti-Dia.
Recipient Genotyping Method
DNA-based typing for common blood group antigens 
was performed by the BLOODchip ID Core XT kit (Progenika 
Biopharma, Derio, Spain) and the Luminex genotyping 
platform (Luminex, Austin, TX), which interrogates 29 
polymorphisms to predict the expression of 37 antigens in 10 
blood group systems. DNA samples were extracted from EDTA 
blood by spin-column separation (QIAmp; QIAGEN, Valencia, 
CA). DNA concentration was determined by measurement of 
optical density at 260 and 280 nm. Extracted DNA was kept at 
–20°C until testing. Samples were processed with one positive 
and one negative control in each run.
Outcome Measures
The primary outcome was to detect new alloantibodies 
after transfusion of antigen-matched units, since RBC allo-
immunization is associated with a risk of hemolytic transfusion 
reaction. According to the treatment guideline for chronically 
transfused patients with thalassemia, a pre-transfusion Hb 
level between 9 and 10.5 g/dL is recommended to promote 
growth, improve physical activities, and suppress abnormal 
bone marrow expansion.15 Therefore, the pre-transfusion 
Hb response to antigen-matched transfusion was assessed. 
Marked improvement was defined as an increase of mean 
pre-transfusion Hb of at least 1 g/dL from 6 months from the 
patient’s enrollment to the last follow-up visit compared with 
that of the 12-month period before enrollment.
Crossmatch problems could delay blood transfusion for 
some patients with thalassemia having an autoantibody or 
antibody to a high-prevalence antigen even though antigen-
matched units for all clinically significant common antibodies 
were issued. Therefore, the secondary outcome was to assess 
the response to crossmatch-positive but antigen-matched RBC 
units. Also, finding antigen-matched units for all clinically 
significant common antibodies was both time and labor 
consuming. We attempted to identify the predictors of patient 
responses to antigen-matched RBC units, such as history of 
three or more antibodies and patient age. 
Patients received regular transfusions every 1–4 weeks. 
Laboratory tests including complete blood count (CBC) 
and ferritin were performed every 3 months. Therefore, 
pre-transfusion Hb was not available at every time point. The 
safety outcome was the incidence of hemolytic transfusion 
reactions. Definition of hemolytic transfusion reaction was 
based on the National Healthcare Safety Network Biovigilance 
Component Hemovigilance Module Surveillance Protocol 
by the U.S. Centers for Disease Control and Prevention.16 
According to our hospital hemovigilance policy, all transfusion 
reactions were reported to the Transfusion Medicine Unit.
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Statistical Analysis
Continuous variables were summarized descriptively 
by means, medians, ranges, and standard deviations (SDs) 
when appropriate. The Wilcoxon signed-rank test was used 
to compare the baseline pre-transfusion Hb and mean pre-
transfusion Hb levels from 6 months after the enrollment. The 
Mann-Whitney U test and Wilcoxon signed-rank test were 
used to compare patient ages between those patients with 
and without pre-transfusion Hb response to antigen-matched 
transfusion.
Statistical analysis of the relationship between predictors 
and the secondary outcome of the patients used bivariate 
comparisons of categorical variables by two-tailed χ2 tests. A 
p value <0.05 was considered statistically significant.
Results
Patient Characteristics
Twenty-four transfusion-dependent patients with tha-
lassemia were initially enrolled; two were later excluded 
because of lack of transfusion. Nineteen (86.4%, 19/22) were 
female. The median age was 24 years (range 2–58 years). 
Thirteen (59.1%, 13/22) patients were diagnosed with 
beta-thalassemia Hb E. Eight patients (36.4%, 8/22) were 
homozygous for beta-thalassemia, and one patient (4.5%, 
1/22) had Hb H Constant Spring. Twelve patients had three 
or more alloantibodies, five had two alloantibodies, four had a 
single alloantibody, and three had no alloantibody. The three 
most common antibodies were anti-Mia, anti-E, and anti-c 
(Table 1). All patients had no previous history of hemolytic 
transfusion reactions or hyperhemolytic transfusion events.
Outcomes of Providing Phenotype-Matched 
Transfusions According to Patient Genotype
Development of new AlloAntiboDies
After the enrollment, there were 717 transfusion episodes 
comprising 1209 antigen-matched units. Blood transfusion to 
each patient ranged from 22 to 119 units. During the median 
follow-up of 25.5 months (range 10–34 months), no new 
alloantibodies were detected.
increAse in pre-trAnsfusion Hemoglobin
Among the 24 patients, 2 patients (patients 22 and 24) had 
not received regular transfusions before the enrollment and 
were excluded. For the remaining 22 patients, there was no 
statistically significant difference between the pre-transfusion 
Hb level before date of enrollment and the level after 6 months 
of antigen-matched transfusions from date of enrollment until 
the last visit (p = 0.455). The mean pre-transfusion Hb level 
before enrollment versus the level after 6 months of antigen-
matched transfusions from enrollment was 7.2 ± 1.8 versus. 
7.4 ± 1.6 g/dL, which was calculated from the total of 166 and 
300 CBC results, respectively. The mean pre-transfusion Hb 
levels for individual patients are shown in Figure 1.
Interestingly, five patients (patients 1, 2, 12, 15, and 
20) showed marked improvement in mean pre-transfusion 
Hb levels (≥1.0 g/dL) compared with levels before the 
enrollment. Of these patients, three patients had three or more 
alloantibodies, one patient had two alloantibodies, and one 
patient had one alloantibody.
Patient 1, with beta-thalassemia Hb E, had multiple anti-
bodies. Her average baseline pre-transfusion Hb was 4.5 g/dL. 
She received antigen-matched transfusions for 26 months. 
Six months after her enrollment, her mean pre-transfusion Hb 
was 5.5 g/dL.
Patient 2, with homozygous beta-thalassemia, had 
multiple antibodies and did not respond well to transfusion. 
Three years previously, he underwent a splenectomy in an 
attempt to maintain better pre-transfusion Hb. Nevertheless, 
his pre-transfusion Hb was unimproved after splenectomy. His 
Fig. 1 Mean pre-transfusion hemoglobin (Hb) levels before 
and after antigen-matched transfusion. Hb levels in g/dL for 22 
regularly transfused thalassemia patients are shown. The mean 
pre-transfusion Hb level before enrollment versus the level after 6 
months of antigen-matched transfusions from enrollment was 7.2 ± 
1.8 versus 7.4 ± 1.6 g/dL. Seventeen patients with no improvement 
in mean pre-transfusion Hb are represented by dashed lines. The 
five patients who showed significant improvement in the mean pre-
transfusion Hb levels (≥1.0 g/dL) are represented by solid lines. 
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years Gender Type of thalassemia Splenectomy
Complications/











1 29 F Beta-
thalassemia 
Hb E
No Iron overload Lea, Leb, E, Mia,  
Fyb, Dia
E–, K–, Fy(b–), S–, 
Mi(a–), Di(a–)
4.5 5.5
2 12 M Homozygous 
beta-
thalassemia





and splenic vein 
thrombosis
Mia, Leb, Jkb, 
unidentified




3 3 F Homozygous 
beta-
thalassemia
No Iron overload E, c, Mia, S E–, c–, K–, Fy(b–), 
N–, S–, Mi(a–), 
Di(a–)
8.9 8.6
4 36 F Beta-
thalassemia 
Hb E
No Iron overload E, c, Mia, S, Jkb E–, c–, K–, Jk(b–), 
Fy(b–), N–, S–, 
Mi(a–), Di(a–)
6.8 7.2
5 40 F Homozygous 
beta-
thalassemia
No Iron overload M, c, K, Jkb, Mia E–, c–, K–, Jk(b–), 
M–, S–, Mi(a–), 
Di(a–)
7.3 6.9
6 39 F Beta-
thalassemia 
Hb E
Yes (23 years 
before the 
study)
Iron overload Lea, Leb, S, 
unidentified 
K–, Fy(b–), N–, S–, 
Di(a–)
6.9 7.4
7 14 M Beta-
thalassemia 
Hb E
No Iron overload E, c, Mia, Dia E–, c–, K–, Fy(b–), 
N–, S–, Mi(a–), 
Di(a–)
7.9 7.7
8 20 F Homozygous 
beta-
thalassemia





E, c, S, Chido E–, c–, K–, N–, S–, 
Di(a–)
8.7 7.4
9 27 M Homozygous 
beta-
thalassemia
Yes (23 years 
before the 
study)
Iron overload E, c, Lea, Fyb E–, c–, K–, Fy(b–), 
S–, Mi(a–), Di(a–)
4.7 3.6
10 42 F Beta-
thalassemia 
Hb E
No Iron overload Jka, Mia,  
unidentified 
C–, K–, Fy(b–), 
Jk(a–), M–, S–, 
Mi(a–), Di(a–)
5.8 6.1
11 53 F Hb H Constant 
Spring










E, c, Mia E–, c–, K–, S–, 
Mi(a–), Di(a–)
9.8 9.7








at spine causing 
neurodeficiency
E, c, Mia E–, c–, K–, Fy(b–), 
Mi(a–), Di(a–)
6.3 7.3
13 58 F Beta-
thalassemia 
Hb E
Yes (13 years 
before the 
study)
Iron overload E, auto-C E–, c–, K–, Jk(b–), 
Fy(b–), S–, Mi(a–), 
Di(a–)
8.1 7.6
14 20 F Homozygous 
beta-
thalassemia






Mia, S E–, c–, K–, Jk(b–), 
S–, Mi(a–)
6.5 7.3
15 20 F Beta-
thalassemia 
Hb E
No Iron overload, 
epilepsy
E, c E–, c–, K–, S–, 
Mi(a–), Di(a–)
3.7 5.1
16 2 F Homozygous 
beta-
thalassemia
No None Jka, unidentified K–, Jk(a–), N–, S–, 
Mi(a–), Di(a–)
9.0 9.2
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baseline pre-transfusion Hb after splenectomy was 7.2 g/dL. 
He received antigen-matched transfusions for 28 months. Six 
months after the enrollment, his mean pre-transfusion Hb 
was 9.1 g/dL.
Patient 12, with homozygous beta-thalassemia, had anti-E, 
anti-c, and anti-Mia. His average baseline pre-transfusion 
Hb was 6.3 g/dL. He received antigen-matched transfusions 
for 14 months. Six months after his enrollment, his mean 
pre-transfusion Hb was 7.3 g/dL. Note that he underwent a 
splenectomy 8 months after the enrollment, however. Seven 
months after splenectomy, his Hb was 9.0 g/dL, and he has not 
received a blood transfusion since then. Thus, the improvement 
of his pre-transfusion Hb could be a result of the splenectomy.
Patient 15, with beta-thalassemia Hb E, had anti-E and 
anti-c. Her average baseline pre-transfusion Hb was 3.7 g/dL. 
She received antigen-matched transfusions for 34 months. Six 
months after this enrollment, her mean pre-transfusion Hb 
was 5.1 g/dL.
Patient 20, with beta-thalassemia Hb E, had anti-E. 
Antigen-negative RBC units for E, c, and Mia were given, but 
his pre-transfusion Hb was unimproved. His baseline pre-
transfusion Hb was 3.7 g/dL. He received antigen-matched 
transfusions for 28 months. Six months after this enrollment, 
his mean pre-transfusion Hb was 4.9 g/dL.
meAn timing between rbc trAnsfusions
The mean timing between transfusions before and after 
antigen-matched transfusion was not statistically different 
(p = 0.426). The patients with Hb responses tended to show 
longer intervals between transfusions, although there was 
one patient (patient 16) who had prolonged timing between 
transfusions with similar pre-transfusion Hb level (Fig. 2). 
This homozygous beta-thalassemia patient had anti-Jka and 
an unidentified antibody. Her average baseline pre-transfusion 
Hb was 9.0 g/dL. She received antigen-matched transfusions 
for 31 months. Six months after this enrollment, her mean pre-
transfusion Hb was 9.2 g/dL. However, the timing between 
transfusions was improved from 14 days before antigen-
matched transfusions to 28.6 days after antigen-matched 
transfusions.





Type of  
thalassemia Splenectomy
Complications/











17 19 F Beta-
thalassemia 
Hb E
No Iron overload E, unidentified E–, c–, K–, Jk(b–), 
Fy(b–), M–, S–, 
Mi(a–), Di(a–)
7.9 8.3
18 7 F Beta-
thalassemia 
Hb E
No Iron overload Chido E–, c–, K–, Jk(b–), 
Fy(b–), S–, Mi(a–), 
Di(a–)
8.7 9.1
19 11 F Beta-
thalassemia 
Hb E




Mia E–, K–, N–, S–, 
Mi(a–), Di(a–)
7.6 7.3
20 35 M Beta-
thalassemia 
Hb E
Yes (22 years 
before the 
study)
Iron overload E E–, c–, K–, Fy(b–), 
S–, Mi(a–), Di(a–)
3.7 4.9
21 28 F Beta-
thalassemia 
Hb E
Yes (23 years 
before the 
study)
Iron overload Nonspecific cold E–, K–, Fy(b–), N–, 
S–, Mi(a–), Di(a–)
8.5 8.9
22 6 F Homozygous 
beta-
thalassemia
No Iron overload No alloantibody E–, c–, K–, Jk(a–), 
N–, S–, Mi(a–), 
Di(a–)
Patient did not receive regular 
transfusion before enrollment; 
excluded from study.
23 17 F Beta-
thalassemia 
Hb E
No Iron overload No alloantibody E–, c–, K–, Fy(b–), 
N–, S–, Mi(a–), 
Di(a–)
9.2 7.6
24 27 F Beta-
thalassemia 
Hb E
No Iron overload No alloantibody E–, c–, K–, Jk(b–), 
N–, S–, Mi(a–), 
Di(a–) 
Patient did not receive regular 
transfusion before enrollment; 
excluded from study.
*Red blood cell phenotype predicted by genotyping method. Hb = hemoglobin.
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Responses to Crossmatch-Positive but Antigen-
Matched Transfusions
Although antigen-matched units for Rh (D, C, c, E, e), Mia, 
M, S, Jka, Jkb, Fya, Fyb, and Dia were issued for all patients, six 
patients (27.3%, 6/22; patients 2, 4, 8, 9, 14, and 18) showed 
positive crossmatch reactions with some units. Five of them 
had autoantibodies, and the other had anti-Chido; all resulted 
in positive crossmatches. In these six patients, there were 210 
transfusion episodes, 74 of which (35.2%) showed positive 
crossmatch results. The grades of the crossmatch reactivity 
(n = 74) were not more than 2+ (median: 1+).
Before this study was performed, autoantibody or 
antibody to a high-prevalence antigen often complicated the 
pre-transfusion process and delayed the transfusion schedule. 
During this study, antigen-matched units for Rh (D, C, c, E, 
e), Mia, M, S, Jka, Jkb, Fya, Fyb, and Dia could be prepared in 
advance; therefore, the patients received transfusions on time.
For the patient with anti-Chido, Chido– RBCs were not 
provided because it is not a clinically significant antibody. For 
the patients with autoantibodies, antigen-matched units were 
found ahead of the transfusion date and the least incompatible 
antigen-matched unit(s) were selected for transfusion on the 
day of transfusion.  
In the 22 patients with negative versus positive cross-
match results, the responses to antigen-matched transfusions 
were not statistically different (p = 1.000). The average 
increase of pre-transfusion Hb in individuals with negative 
versus positive crossmatch was 0.20 g/dL (SD 0.74) versus 
0.18 g/dL (SD 1.22), respectively. Moreover, no acute or 
delayed hemolytic transfusion reactions were detected in 
those six patients with positive crossmatch transfusions.
Predictors of Responses to Antigen-Matched 
Transfusions
We hypothesized that patients with three or more anti-
bodies would respond well to antigen-matched transfusions. 
However, the response to antigen-matched transfusions 
between those patients with versus those patients without 
three or more antibodies was not statistically significant 
among the 22 patients (p = 0.523). The average increase of 
pre-transfusion Hb in these two patient groups was 0.15 g/dL 
(SD 0.91) versus 0.25 g/dL (SD 0.86), respectively.
This study determined that the age of the patient before 
this enrollment could not be a predictor for successful antigen-
matched transfusions (p = 0.651). The mean age of individuals 
with versus individuals without increases in pre-transfusion 
Hb after enrollment was 22.3 years (SD 11.7) versus 26.8 
years (SD 16.4), respectively.
Discussion
To the best of our knowledge, this is the first report of 
clinical outcomes of phenotype-matched transfusions to 
multiply transfused patients with thalassemia guided by 
patient DNA-based typing. Of the 22 patients without serologic 
phenotypes, data before the first transfusion were included, 
and no new alloantibodies were detected. Hb levels of five 
patients were increased, and one patient required less frequent 
transfusions after receiving antigen-matched transfusions, 
suggesting a prolongation of transfused erythrocyte survival 
(5 of 22 evaluable patients, or 22.7% response rate), although 
there was no significant change for the entire group. The fifth 
patient with Hb improvement also underwent a splenectomy 
and, therefore, the effect of this protocol cannot be determined.
Successful maintenance of pre-transfusion Hb in 
chronically transfused patients with thalassemia is an 
important goal for better quality of life, lower frequency of 
transfusion, lower serum ferritin, and fewer transfusion 
reactions.15,17 RBC alloimmunization is a challenge when 
providing compatible blood units. Although many factors 
Fig. 2 Mean timing between transfusions before and after antigen-
matched transfusions. The timing between transfusions in 22 
regularly transfused patients with thalassemia is shown in days. 
Seventeen patients with no improvement in mean pre-transfusion 
hemoglobin (Hb) are represented by dashed lines. However, one 
of these patients showed markedly longer intervals between 
transfusions after antigen matching (arrow). Five patients who 
showed significant improvement in the mean pre-transfusion Hb 
levels (≥1.0 g/dL) are represented by solid lines. 
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contribute to this undesirable event, the most important factor 
is the exposure to foreign RBC antigens.18,19 Therefore, antigen-
matched transfusion is a goal for success. Additionally, the 
efficacy of transfusion for chronically transfused patients 
with thalassemia could be affected by the timing between 
transfusions and host factors, such as splenectomy and 
comorbidities, as well as the presence of precipitating factors, 
such as infections.
Because the baseline serologic phenotype of most patients 
is unavailable, a report of regularly transfused Thai patients 
with thalassemia showed that the presence of circulating 
donor RBCs leads to mixed-field reactivity and inaccurate 
results.20 Discrepancies between serologic phenotypes 
performed by different laboratory personnel at different time 
points of testing were also observed. Therefore, DNA-based 
typing offers an advantage over traditional serologic typing 
to accurately predict the identity of the patient’s RBC antigens 
after recent transfusion. Moreover, DNA-based typing may 
provide benefits to patients with autoantibodies, multiple 
alloantibodies, antibodies to high-prevalence antigens, or 
antibodies against antigens with unavailable antisera.8
The extended molecular-matched RBC transfusion for 
chronically transfused patients can improve the effectiveness 
of transfusion by decreasing the alloimmunization rate.17,21 
Despite these benefits, this approach is currently not widely 
available in Thailand because of the high cost for genotyping a 
large inventory of donor RBCs. Therefore, DNA-based typing 
is only performed for patients, and phenotype-matched units 
are provided according to patient genotyping data.
Finding compatible blood units for patients with multiple 
alloantibodies is laborious and time-consuming. After protocol 
implementation, antigen-matched units were procured before 
the planned patient visits. Although some crossmatches 
revealed serologic incompatibility due to autoantibody 
or clinically insignificant antibody to a high-prevalence 
antigen, blood units were issued on time because all clinically 
significant antigens were matched. The least incompatible 
antigen-matched units from the donor inventory would be 
transfused to the patient, and the antibody identification 
retested on every visit. The transfusion of incompatible RBC 
units is not a standard practice. However, it is not possible 
in some patients with autoantibody or clinically insignificant 
antibody to high-prevalence antigen to provide compatible 
units. In this case, administration of antigen-negative RBC 
units is the recommended approach. Interestingly, hemolytic 
transfusion reactions were not detected in our patients under 
this protocol.
Prophylactic antigen-matching has been shown to reduce 
new antibody formation.11,22 A recent study in patients with 
sickle cell disease in the United States showed new antibody 
formation for the unmatched antigens.21 We matched only 
common clinically significant RBC antigens in Thailand, but 
no new alloantibodies were detected. One explanation is the 
ethnic differences between donors and patients in the United 
States.23 Sickle cell disease affects mainly African Americans, 
whose blood donation rates are only 25–50 percent of those of 
white individuals.24 In Thailand, blood donors share the same 
ethnicity with the patients. Therefore, there is a better chance 
to obtain phenotype-matched blood units for Thai patients 
with thalassemia. 
The predictors of good responses to antigen-matched 
blood could not be identified. The number of patients in 
our study was probably too small to find weak predictors. 
Therefore, p values need to be interpreted carefully. Future 
multicenter studies are required. Another limitation of our 
study was the frequency of blood transfusions. One patient 
did not receive a blood transfusion as scheduled after the 
enrollment, which affected the mean pre-transfusion Hb level.
To apply this study into our routine work, DNA-based 
typing should be performed for chronically transfused patients 
with thalassemia who have no available phenotyping data. 
The extended antigen-matched transfusion could apply to 
patients with multiple antibodies, autoantibody, or a clinically 
insignificant antibody to a high-prevalence antigen but not for 
patients without antibody. This practice will help the majority 
of patients with difficult pre-transfusion testing to receive 
blood on schedule.
In conclusion, DNA-based typing is helpful in transfusion 
management of chronically transfused patients with 
thalassemia, especially when phenotype data are unavailable. 
The genotype data allow us to provide antigen-matched units 
despite a positive crossmatch. In this study, no new alloanti-
bodies were detected after the median follow up of 25.5 
months and average number of 50 units/patient. A subgroup 
of patients showed increases in pre-transfusion Hb. A larger 
prospective clinical trial is needed to evaluate the definitive 
role of DNA-based typing in transfusion-dependent patients 
with thalassemia.
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